Home / News
ASCO 2026
Daraxonrasib Improves Survival Outcomes in Previously Treated Metastatic PDAC
Therapeutic options for metastatic pancreatic ductal adenocarcinoma (PDAC) remain limited, with second-line treatments typically yielding modest benefit. Activation of the RAS pathway, most commonly driven by KRAS mutations, occurs in the vast majority of PDAC cases and represents a critical oncogenic dependency. Daraxonrasib, an oral, multi-selective RAS(ON) inhibitor targeting the active, GTP-bound state of RAS,...
June 1, 2026
All FDA Approvals
All Cancer Types Endometrial Cancer Hematologic Malignancies Leukemia Lymphoma Multiple Myeloma Non-Small Cell Lung Cancer Prostate Cancer
All Diagnostics + Biomarkers Screening
All Therapeutic Approaches Chemotherapy Immunotherapy Targeted Therapy
North American Enrollment in Clinical Trials
Clinical Trials

North American Enrollment in Clinical Trials

Dr. Ming-Hei Tai April 15, 2026
  • 1
  • 2

What are you looking for?

Popular Searches

Oncology Practice Management Navigation